CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Latest News

Long-term data reinforce Aimovig (erenumab) efficacy

Long-term analyses from pivotal studies of Aimovig (erenumab) have demonstrated sustained efficacy at 1-year follow-up.

Read more »


Expanded data support Emgality (galcanezumab) in episodic cluster headache

Emgality (galcanezumab) has been shown to improve episodic cluster headache across a range of parameters at week 3 of treatment.

Read more »


Ajovy (fremanezumab) efficacy and safety maintained over 12 months

Monthly and quarterly treatment with Ajovy (fremanezumab) reduces mean monthly migraine days over 12 months in both episodic and chronic migraine, according to long-term data on 1890 patients, of whom 1278 had completed previous placebo-controlled studies of fremanezumab and 312 were new patients.

Read more »


Eptinezumab consistently demonstrates rapid onset of migraine prevention

Eptinezumab has consistently demonstrated rapid onset of migraine prevention on day 1 of treatment, and benefits maintained through to week 4, across four double-blind, placebo-controlled randomised trials.

Read more »


Ubrogepant well tolerated in acute migraine treatment studies

Ubrogepant was well tolerated following intermittent, high frequency dosing in a Phase 1 double-blind, parallel-group study in healthy volunteers aged 18-50 years with no significant medical history and normal hepatic function.

Read more »


Oral atogepant significantly reduces migraine days

Oral atogepant significantly reduced mean migraine days (MMD) across all dosing schedules in a Phase 2b/3 study of migraine prevention.

Read more »


Emgality (galcanezumab) benefits reported in both low- and high-frequency migraine headache

Pooled data from the EVOLVE 1 and 2 studies of Emgality (galcanezumab) have shown the benefits of treatment in patients with both low- and high-frequency episodic migraine (4-<8 vs 8-14 monthly migraine headache days [MMHD]).

Read more »



For all the other recent migraine news featured on the CGRP Forum click here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Logos
© Copyright CGRP Forum 2019. Please click here to unsubscribe from future mailings.
‚Äč